When it Comes to Treating Ulcerative Colitis, US Gastroenterologists May be Betting it All on JAK…
November 30, 2023 10:59 ET
|
Spherix Global Insights
Exton, Pennsylvania, Nov. 30, 2023 (GLOBE NEWSWIRE) -- With the Ulcerative Colitis (UC) market set to heat up in the coming months, the JAK class seems poised to become a dominant treatment,...
With Little Remaining Unmet Need for Injectable Biologics for the Treatment of Plaque Psoriasis, US Dermatologists Report the Future is Oral, According to Spherix Global Insights
August 31, 2023 16:35 ET
|
Spherix Global Insights
Exton, Pennsylvania, Aug. 31, 2023 (GLOBE NEWSWIRE) -- The biologic treatment armamentarium for plaque psoriasis has arguably experienced some of the most successful developments in recent...
CURE Media Group Announces the 2023 Extraordinary Healer® Award Finalists
March 28, 2023 15:02 ET
|
CURE Media Group
SAN ANTONIO, Texas, March 28, 2023 (GLOBE NEWSWIRE) -- CURE®, the industry-leading multimedia platform devoted to cancer updates and research that reaches more than 1 million patients, survivors and...
CURE Media Group announces D.L. Hughley as keynote panel moderator for the 2022 Multiple Myeloma Heroes and Health Equity Heroes awards
December 05, 2022 13:38 ET
|
CURE Media Group
CRANBURY, N.J., Dec. 05, 2022 (GLOBE NEWSWIRE) -- CURE Media Group, the industry-leading multimedia platform devoted to providing cancer updates and research to the more than 1 million patients,...
Top NoSQL Innovators Honored with ScyllaDB Awards
February 16, 2022 08:58 ET
|
Scylla DB, Inc.
PALO ALTO, Calif., Feb. 16, 2022 (GLOBE NEWSWIRE) -- ScyllaDB, the company behind the ScyllaDB database for data-intensive apps that require high performance and low latency, today announced the...
Dyadic Announces Research, License and Collaboration Agreement with Janssen for the Manufacture of Therapeutic Protein Candidates using its C1 Platform
December 17, 2021 07:00 ET
|
Dyadic International, Inc.
JUPITER, Fla., Dec. 17, 2021 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further...
MacroGenics Enters Research Collaboration with Janssen to Develop Novel DART® Molecule
December 18, 2020 07:30 ET
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 18, 2020 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ: MGNX), a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based...
Aleafia Health Approved by Janssen Pharmaceuticals to Administer Antidepressant SPRAVATO®
July 24, 2020 07:15 ET
|
Aleafia Health Inc.
SPRAVATO® (esketamine) nasal spray uses the first new mechanism of action in decades to treat treatment resistant depression disorder Aleafia Health medical clinics along with select physicians and...
Minerva Neurosciences Exercises Right to Opt Out of Agreement With Janssen for Seltorexant (MIN-202)
July 01, 2020 08:00 ET
|
Minerva Neurosciences, Inc
Preserves royalties payable to Minerva on worldwide sales of seltorexant Eliminates all financial obligations with respect to the clinical development and commercialization of seltorexantCorporate...
Telix Pharmaceuticals and GenesisCare Commence ENHANCING Prostate Cancer Clinical Study
August 07, 2019 20:00 ET
|
Telix Pharmaceuticals Limited
MELBOURNE, Australia and SYDNEY, Australia, Aug. 08, 2019 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX.TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on...